Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease

Summary

This is a phase 2, randomized, double-blind, multicenter study to assess the therapeutic efficacy, safety, and mechanisms of omilancor (BT-11) in patients with moderate to severe Crohn's Disease (CD).

Timeline

Start

2021-11

Primary completion

2022-02

Completion

2022-02

Outcome

Outcome not reported

Stopped: “Decision by Landos Biopharma (not related to safety or efficacy)”

Drugs

Indications